Beyond Steroids: Clinical Trial Results on the Next Generation Agents for Atopic Dermatitis

EP: 1.Recognizing and Diagnosing Atopic Dermatitis With Confidence

EP: 2.A Practical Guide to Atopic Dermatitis Differential Diagnosis

EP: 3.Quantifying Atopic Dermatitis in Practice: Evaluating Patient Disease Severity

EP: 4.Soothing the Skin: Wellness Practices for Atopic Dermatitis Management

EP: 5.The Topical Toolbox: A Review of Atopic Dermatitis Treatment Options

EP: 6.TCS and TCIs: Benefits, Risks, and Real-World Uses for Atopic Dermatitis

Now Viewing

EP: 7.Beyond Steroids: Clinical Trial Results on the Next Generation Agents for Atopic Dermatitis

EP: 8.Tailoring Treatment: Personalizing Topical Therapy for Patients With Atopic Dermatitis

EP: 9.Stronger Together: Collaborating with Dermatologists for Better Outcome

EP: 10.Real Cases, Key Takeaways: Applying Atopic Dermatitis Insights in Clinical Practice

Video content above is prompted by the following:

Roflumilast represents a significant advancement in PDE4 inhibitor therapy for atopic dermatitis, offering 25-300 times greater potency than crisaborole. Approved for patients six years and older, this once-daily cream provides superior patient compliance compared to twice-daily crisaborole applications. The elegant cream formulation feels moisturizing rather than greasy like crisaborole's ointment base, addressing common tolerability issues that limit treatment adherence in atopic dermatitis management.

Ruxolitinib cream, a JAK1/2 inhibitor approved for ages 12 and up, demonstrates exceptional efficacy in treating mild-to-moderate atopic dermatitis. Clinical trials show this twice-daily topical outperforms triamcinolone in head-to-head comparisons, achieving clear or almost-clear skin in over 50% of patients within eight weeks. The drug's unique homeostatic mechanism prevents immediate disease rebound upon discontinuation, with patients maintaining remission for several months—a distinctive advantage over traditional corticosteroids.

Tapinarof introduces an innovative aryl hydrocarbon receptor agonist mechanism, approved for patients two years and older as a once-daily cream. While slower-acting than other non-steroidal options, tapinarof achieves mid-40% clear or almost-clear rates at eight weeks with excellent itch control. The medication's unique benefit includes sustained remission periods after achieving clearance, though practitioners should monitor for folliculitis—an acne-like eruption that resolves upon temporary treatment discontinuation.